- Home
- DGICB vs GOSS Comparison
DGICB vs GOSS Comparison
Compare DGICB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | GOSS |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.4M | 615.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DGICB | GOSS |
|---|---|---|
| Price | $15.29 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $4.91 |
| AVG Volume (30 Days) | 1.1K | ★ 26.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ 78.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $114,701,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.84 | $0.33 |
| 52 Week High | $20.30 | $3.87 |
Technical Indicators
Market Signals| Indicator | DGICB | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 23.01 |
| Support Level | $13.73 | $0.33 |
| Resistance Level | $17.80 | $0.60 |
| Average True Range (ATR) | 0.65 | 0.08 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 0.00 | 9.07 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.